bioz476: genomic medicine

What is the specific genetic cause of sickle cell disease at the protein level?

An $E6V$ missense mutation in the beta-globin chain, which replaces glutamate with valine at position 6.

Why is autologous gene addition therapy preferred over traditional stem cell transplantation for sickle cell patients?

Autologous gene therapy utilizes the patient's own genetically modified cells, eliminating the need to find an HLA-matched donor and avoiding the risk of immune-mediated rejection.

What therapeutic gene is introduced into autologous stem cells in LentiGlobin gene addition therapy?

The ̢̢\beta^{A-T87Q}̢̢ globin gene ($HbA^{T87Q}$), delivered via a lentiviral vector.

How does the single amino acid substitution in $HbA^{T87Q}$ protect red blood cells against sickling?

The substitution of threonine with glutamine at position 87 ($\beta 87\text{Thr} \rightarrow \beta 87\text{Gln}$) sterically inhibits the polymerization of sickle hemoglobin ($HbS$) while maintaining wild-type oxygen affinity.

What change in the rate of severe vaso-occlusive events was observed in patients after receiving LentiGlobin infusion?

The median annualized rate of severe vaso-occlusive events dropped from $3.5$ (range $2.0\text{--}13.5$) prior to enrollment to $0.0$ (range $0.0\text{--}0.0$) after treatment.

What are the major timeline phases involved in receiving LentiGlobin therapy?

Insurance approval ($1\text{--}3$ months), chronic exchange transfusion ($2$ months), apheresis collections ($1\text{--}2$ months), stem cell processing ($2\text{--}6$ months), and inpatient admission ($35\text{--}75$ days).

What is the estimated per-patient cost of LentiGlobin gene therapy?

Approximately $\\n2.2\text{ million}$.

What are the key clinical features and mortality rate of pancreatic ductal adenocarcinoma (PDAC)?

PDAC is lethal in $88\%$ of patients, recurs rapidly after surgical resection, exhibits low T-cell infiltration, and is largely unresponsive to immune checkpoint inhibitors.

What is autogene cevumeran and how does it work?

Autogene cevumeran (BNT122/RO7198457) is an individualized mRNA-lipoplex vaccine encoding up to 20 patient-specific neoantigens designed to stimulate target-specific T cells against pancreatic cancer.

What treatment protocol was administered in the autogene cevumeran clinical trial for resected PDAC?

One dose of atezolizumab at week 6, priming doses 1--8 of autogene cevumeran (weeks 9--17), 12 cycles of biweekly mFOLFIRINOX chemotherapy (weeks 21--43), and a booster dose at week 46.

How did recurrence-free survival (RFS) compare between responders and non-responders in the autogene cevumeran trial?

Responders achieved a median RFS that was not reached, compared to a median RFS of $13.4\text{ months}$ in non-responders ($P = 0.007$, hazard ratio $0.14$).

What metabolic disorder affected Baby KJ, and what is its primary dangerous clinical sign?

Carbamoyl-phosphate synthetase 1 (CPS1) deficiency, an ultra-rare inborn error of metabolism affecting the urea cycle that leads to hyperammonemia (lethal levels of ammonia in the blood).

Where is the CPS1 enzyme located and what physiological role does it perform?

CPS1 is located in the mitochondria of hepatocytes (liver cells) and initiates the conversion of toxic ammonia into urea in the first step of the urea cycle.

What compound was administered to manage plasma ammonia levels during Baby KJ's clinical course?

Glycerol phenylbutyrate.

What specific point mutations were identified in Baby KJ's CPS1 alleles?

Paternal allele: $c.1003C \rightarrow T$ ($Q335X$ stop codon); Maternal allele: $c.2140G \rightarrow T$ ($E714X$).

How was adenine base editing designed to repair Baby KJ's paternal $Q335X$ mutation?

An adenine base editor targeted the antisense strand to perform an $A \rightarrow G$ conversion, repairing the stop codon $TAG$ back to the glutamine-encoding codon $CAG$ ($Q335$).

What molecular components comprised the custom base editor construct (NGC-ABE8e-V106W) created for Baby KJ?

A Cas9(D10A) nickase fused to an evolved TadA monomer deaminase, guided by the single guide RNA 'kayjayguran' and encapsulated inside lipid nanoparticles (LNPs).

Which three preclinical biological models were used to validate the safety and efficiency of the CPS1 base-editing drug?

HuH-7 liver cells engineered with $Q335X$ (in vitro proof-of-concept), Rosa26-Q335X transgenic mice (in vivo hepatic editing efficiency), and cynomolgus monkeys (in vivo toxicity and biodistribution).

What off-target nomination methodologies were integrated to evaluate candidate off-target editing sites for Baby KJ's therapy?

What process for off-target nomination and tiering is depicted in this workflow diagram?